Trevi Therapeutics, Inc. (TRVI) - Forward P/S Multiple
Trevi Therapeutics possesses pricing power due to the unique action of Haduvio. The development utilizes algorithms, although tests require physician participation. Currently, the company relies on investor capital until patents are secured. The forward P/S ratio helps assess the price trend relative to future sales, with the current value equal to , which cautions against buying the asset at its peak.
Financial and market metric breakdowns for Trevi Therapeutics (TRVI)
- current price and projected stock value:
- market capitalization indicators:
- issuer book value statistics:
- debt and liquidity data:
- business earnings and investment ratios data:
TRVI - Net Financial Result|Projected Future Earnings Trevi Therapeutics|TRVI - Price to Earnings Ratio|Future Price to Earnings trevitherapeutics.com|TRVI - Growth-Adjusted Market Cap to Net Income|Enterprise Value to EBITDA Ratio Trevi Corp|TRVI - Company profit before taxes, interest and amortization|Earnings per share for the last twelve months Trevi Therapeutics|TRVI - Earnings per share for the trailing year|Year-over-year net earnings per share growth for the last 12 months trevitherapeutics.com|TRVI - Earnings per share growth in current year|Earnings growth forecast for next year Trevi Therapeutics
- company sales and revenue statistics:
Initial company analysis:Trevi Therapeutics Inc (TRVI)
For an investor in Trevi Therapeutics (TRVI), the balance between current capitalization and the commercialization potential of its drugs is key. This ratio compares the business's market value with expected future sales volumes, determining the extent of expectations already priced in. By analyzing the issuer's forward P/S, one can identify unjustified premiums for scalability. For a biotech company with low post-approval costs, this indicator is critical for assessing the adequacy of the market valuation.
Competitors of Trevi Therapeutics
Forward P/S Multiple BIIB (Biogen Idec)|Market Cap to Expected Sales Ratio Neurocrine Corp (NBIX)|RGC: Forward Price-to-Revenue Multiple|Forward Price to Sales AXSM (Axsome Therapeutics)|ACAD: Forward P/S Multiple|Xenon Pharmaceuticals Inc. - Forward Price to Sales|Price-to-Projected Revenue Ratio Viking Pharma|SUPN: Forward Price to Sales|Forward P/S Multiple CPRX|Forward P/S Multiple denalitherapeutics.com (DNLI)|Forward P/S Multiple HRMY (Harmony Biosciences Inc)|Market Cap to Expected Sales Ratio Biohaven (BHVN)|Amylyx Corp - Forward P/S Multiple|Market Cap to Expected Sales Ratio Praxis Corp PRAX|AVXL: Forward P/S Multiple|CBLL (ceribell.com) - Price-to-Projected Revenue Ratio|PRTA (Prothena Corporation) - Forward P/S Multiple|Forward Price-to-Revenue Multiple alector.com (ALEC)|Price-to-Projected Revenue Ratio Annexon, Inc. (ANNX)|OMER - Market Cap to Future Revenue Ratio|Forward P/S Multiple NGNE (Neurogene Inc)|AC Immune (ACIU) - Market Cap to Future Revenue Ratio|Voyager Therapeutics Inc - Forward P/S Multiple|Neumora (NMRA) - Forward Price-to-Revenue Multiple|SCLX: Forward P/S Multiple|TVGN - Market Cap to Expected Sales Ratio|ACOG (Alpha Cognition Inc) - Forward P/S Multiple|Forward Price-to-Revenue Multiple cogrx.com (CGTX)|Price-to-Projected Revenue Ratio Inhibikase Therapeutics Inc (IKT)|Market Cap to Expected Sales Ratio Cassava Sciences|Forward P/S Multiple ASRT (Assertio Holdings)|COYA - Forward Price-to-Revenue Multiple|vistagen.com - Forward P/S Multiple|OVID: Price-to-Projected Revenue Ratio|Acumen Pharmaceuticals, Inc (ABOS) - Price-to-Projected Revenue Ratio|CervoMed Inc - Forward Price to Sales|Price-to-Projected Revenue Ratio Alterity Therapeutics Limited|clene.com (CLNN) - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple PEPG (PepGen Inc)|Forward P/S Multiple jupiterneurosciences.com (JUNS)|Price-to-Projected Revenue Ratio Relmada Therapeutics, Inc. RLMD|ANVS: Market Cap to Projected Revenue|Grace Tx - Forward P/S Multiple|AIFF (Firefly Neuroscience Inc) - Market Cap to Projected Revenue|KLTO: Forward P/S Multiple|NeuroSense Therapeutics, Ltd. (NRSN) - Forward P/S Multiple|Price-to-Projected Revenue Ratio Reviva Pharmaceuticals, Inc.|Forward Price-to-Revenue Multiple metaviatx.com (MTVA)|Forward P/S Multiple NRXS|HSDT - Market Cap to Future Revenue Ratio|Passage Bio, Inc. - Forward Price-to-Revenue Multiple|bionomics.com.au (NEUP) - Market Cap to Future Revenue Ratio|Minerva - Forward P/S Multiple|Forward Price to Sales ATHA (Athira Pharma Inc)|ADXN: Forward P/S Multiple|Market Cap to Projected Revenue ALZN|CYCN (Cyclerion Therapeutics Inc.) - Forward P/S Multiple|PTIX (Protagenic Therapeutics) - Price to Expected Revenue Ratio|Forward P/S Multiple KTTA|Market Cap to Expected Sales Ratio Cortigent|Forward P/S Multiple ATXI (avenuetx.com)|BrainStorm Cell Therapeutics Inc. - Price-to-Projected Revenue Ratio|Cara Therapeutics Inc. - Forward P/S Multiple|Chromocell Therapeutics (CHRO) - Forward Price-to-Revenue Multiple|ELYM: Forward P/S Multiple|Forward Price-to-Revenue Multiple Intra-Cellular Therapies Inc.|LBPH (Longboard Pharmaceuticals Inc) - Forward P/S Multiple|Marinus - Future Price to Revenue|Forward P/S Multiple NKGN|NRBO (NeuroBo Pharmaceuticals) - Forward Price to Sales|Forward P/S Multiple SAGE (Sage Therapeutics Inc)|Market Cap to Expected Sales Ratio Synaptogenix Inc. (SNPX)|TRVN - Price-to-Projected Revenue Ratio|vigilneuro.com (VIGL) - Forward Price-to-Revenue Multiple|WENA: Forward P/S Multiple|Cerevel Therapeutics, Inc. (CERE) - Forward P/S Multiple
